Cargando…

Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer: A meta-analysis

BACKGROUND: This meta-analysis was performed to compare efficacy and tolerability between antiprogrammed cell death (PD-1)/programmed cell death-ligand-1 (PD-L1) + anticytotoxic T-lymphocyte-associated protein-4 (CTLA-4) treatment and chemotherapy in advanced lung cancer. METHODS: Cochrane Library,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Pei-Pei, Wang, Juan, Ding, Da-Zhi, Zhang, Li, Cheng, Chun, Chen, Da-Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	4200
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416009/ https://www.ncbi.nlm.nih.gov/pubmed/34477154 http://dx.doi.org/10.1097/MD.0000000000027121

Ejemplares similares

Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review
por: Chen, Wei-xun, et al.
Publicado: (2019)

The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient: A protocol for systematic review
por: Zhao, Suyue, et al.
Publicado: (2020)

Efficacy and safety of two different adjuvant chemotherapy regimens in combination with concurrent chemoradiotherapy in treating patients with advanced nasopharyngeal carcinoma: A protocol for randomized controlled trial
por: Zhang, Lu-Lu, et al.
Publicado: (2021)

PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer
por: Guo, Luyong, et al.
Publicado: (2022)

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis
por: Zhang, Min, et al.
Publicado: (2023)

Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: A meta-analysis
por: Zhang, Pei, et al.
Publicado: (2017)

Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
por: Xu, Li, et al.
Publicado: (2022)

Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor
por: Li, Hui, et al.
Publicado: (2020)

Evaluation of efficacy and safety of propofol in the treatment of procedural sedation/anesthesia in neonates: A protocol for systematic review and meta-analysis
por: Yu, Pei-Xia, et al.
Publicado: (2021)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

Evaluation of efficacy and safety of chemotherapy in the treatment of recurrent or resistant gestational trophoblastic neoplasia: A protocol for systematic review and meta-analysis
por: Luo, Fang, et al.
Publicado: (2021)

Computational study on natural compounds inhibitor of c-Myc
por: Ren, Junan, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis
por: Luo, Wenqing, et al.
Publicado: (2021)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Impact of nonsteroidal aromatase inhibitors on steroid profile in a Chinese population
por: Xing, Yanyi, et al.
Publicado: (2017)

Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis
por: Qiangzhao, Liu, et al.
Publicado: (2020)

Effectiveness and safety of chemotherapy combined with immunomodulatory therapies for multiple myeloma: A protocol for systematic review and meta-analysis
por: Deng, Jie, et al.
Publicado: (2022)

A comparative study of the efficiency and safety of chemotherapy as a therapeutic method for recurrent or resistant gestational trophoblastic neoplasia: A protocol for systematic review and meta-analysis
por: Jiang, Tian-Yue, et al.
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment
por: Gu, Hangye, et al.
Publicado: (2023)

Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study
por: Peng, Yen-Chun, et al.
Publicado: (2016)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of OSAS children
por: Yang, Da-Zhi, et al.
Publicado: (2017)

Evaluation of efficacy and safety of combined rosuvastatin and atorvastatin in treating with coronary heart disease: A protocol for systematic review and meta-analysis
por: Li, Ke, et al.
Publicado: (2021)

Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
por: Qian, Da, et al.
Publicado: (2023)

The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis
por: Wu, Lin-guang-jin, et al.
Publicado: (2021)

The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy: A systematic review and meta-analysis
por: Zhang, Kai-Ping, et al.
Publicado: (2021)

Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis
por: Li, Bingxue, et al.
Publicado: (2021)

Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients
por: Zhang, Shuxiao, et al.
Publicado: (2023)

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Man Cai, et al.
Publicado: (2014)

Cervical intervertebral disc herniation treatment via radiofrequency combined with low-dose collagenase injection into the disc interior using an anterior cervical approach
por: Wang, Zhi-Jian, et al.
Publicado: (2016)

Biosimilar erythropoietin in anemia treatment (BEAT)—Efficacy and safety of a 1:1 dose conversion from EPREX(®) to EPIAO(®) in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study
por: Miao, Bolong, et al.
Publicado: (2022)

Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Meta-Analysis
por: Liu, Meng-Dong, et al.
Publicado: (2015)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018)

Safety profiles and adverse reactions of azithromycin in the treatment of pediatric respiratory diseases: A systematic review and meta-analysis
por: Sun, Ying-wen, et al.
Publicado: (2023)

Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer: Study protocol for a prospective, multicenter, open-label
por: Cui, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b2orkr1s6kevg272v55lbaghk4